Key Points
- Director Jeffrey Dunn sold 20,000 SiBone shares on Jan. 8 at an average price of $21.28, generating $425,600 and reducing his stake by about 19.98% to 80,115 shares (≈$1.70M).
- SiBone beat last quarter's estimates with EPS of -$0.11 vs. -$0.16 expected and revenue of $48.66M vs. $46.67M, but remains unprofitable with negative margins and a projected full-year EPS around -$0.78.
- Analyst and institutional sentiment is generally positive—five Buys and one Sell with a consensus rating of "Moderate Buy" and an average price target of $25—while institutional investors own about 98.11% of the stock.
SiBone (NASDAQ:SIBN - Get Free Report) Director Jeffrey Dunn sold 20,000 shares of the company's stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $21.28, for a total transaction of $425,600.00. Following the sale, the director directly owned 80,115 shares of the company's stock, valued at approximately $1,704,847.20. This represents a 19.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
SiBone Stock Performance
Shares of SIBN opened at $17.87 on Tuesday. The company has a market capitalization of $775.38 million, a PE ratio of -35.04 and a beta of 0.69. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.97 and a quick ratio of 6.62. SiBone has a one year low of $12.49 and a one year high of $21.89. The company's fifty day moving average price is $18.99 and its 200 day moving average price is $17.11.
SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The company had revenue of $48.66 million for the quarter, compared to the consensus estimate of $46.67 million. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%. As a group, analysts expect that SiBone will post -0.78 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages have recently commented on SIBN. Truist Financial upped their price target on SiBone from $21.00 to $23.00 and gave the stock a "buy" rating in a report on Thursday, December 18th. Canaccord Genuity Group upped their target price on shares of SiBone from $26.00 to $27.00 and gave the company a "buy" rating in a research note on Wednesday, December 17th. Needham & Company LLC increased their price target on shares of SiBone from $24.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, December 16th. Morgan Stanley raised their price target on shares of SiBone from $20.00 to $23.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 2nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SiBone in a research report on Monday, December 29th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $25.00.
Get Our Latest Research Report on SiBone
Institutional Investors Weigh In On SiBone
A number of institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in SiBone by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company's stock valued at $343,000 after buying an additional 1,053 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in SiBone in the first quarter valued at about $225,000. Goldman Sachs Group Inc. increased its stake in SiBone by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company's stock valued at $5,328,000 after acquiring an additional 83,919 shares during the period. Jane Street Group LLC acquired a new position in SiBone in the first quarter worth about $1,818,000. Finally, Rhumbline Advisers lifted its position in shares of SiBone by 3.6% during the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock worth $838,000 after buying an additional 2,100 shares during the period. Institutional investors and hedge funds own 98.11% of the company's stock.
About SiBone
(
Get Free Report)
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
